Immunoglobulin, Antibody, Or Fragment Thereof, Other Than Immunoglobulin Antibody, Or Fragment Thereof That Is Conjugated Or Adsorbed Patents (Class 530/387.1)
  • Patent number: 11059874
    Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: July 13, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
  • Patent number: 11052165
    Abstract: The invention discloses a method for virus clearance of a cell culture medium, comprising the steps of: i) providing a bulk medium portion, comprising amino acids and glucose, and a first additive portion, comprising vitamins in aqueous solution; ii) subjecting the bulk medium portion to a high temperature short time treatment (HTST); iii) passing the first additive portion through a virus retentive filter or an ultrafilter; and iv) after steps ii) and iii), mixing the bulk medium portion with the first additive portion to obtain a cell culture medium.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 6, 2021
    Assignee: Global Life Sciences Solutions USA LLC
    Inventors: Andreas Castan, Colin R. Tuohey
  • Patent number: 11046784
    Abstract: The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: June 29, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana
  • Patent number: 11046769
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 29, 2021
    Assignee: COMPASS THERAPEUTICS LLC
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • Patent number: 10993459
    Abstract: A method for unlocking bioactive proteins that can then be used to activate natural remedies. The method includes starting with Silica salt and water mixture. Then a base of whey protein concentrate is added to the mixture. The pH of the whey protein mixture is raised using a base. The pH is held at a level above 11 for at least two hours. After at least two hours an acid is then added to the mixture to bring the pH of the mixture below 3 pH. This will stop the activation process. After the unattached proteins are removed the protein mixture is then brought back to a normal pH level, around 4 pH.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 4, 2021
    Inventor: Ralph Yoder
  • Patent number: 10982006
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • Patent number: 10975157
    Abstract: The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 13, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Yifei Zhu, Zhiming Liao, Robert Pytela
  • Patent number: 10975163
    Abstract: The present invention provides compositions and methods for increasing the permeability of a stroma around a neoplasm, and particularly to cancer cells associated with solid tumors. In one embodiment, combining a therapeutic IgE antibody with an anti-cancer agent in accordance with the invention increases the delivery of the anticancer agent to the site of, for example, a solid tumor in a subject. In one embodiment, combining a therapeutic IgE antibody with an anti-cancer agent in accordance with the invention potentiates a tumor's responsiveness and sensitivity to the anti-cancer agent.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 13, 2021
    Inventors: Ragupathy Madiyalakan, Christopher F. Nicodemus, Michael A Hollingsworth
  • Patent number: 10927183
    Abstract: Provided are antibodies and antigen-binding fragment thereof that bind to VSIG4. Various in vitro and in vivo methods and compositions related to antibodies. Methods include prevention and/or therapeutic treatment of cancer using an antibody or an antigen-binding fragment that binds to VSIG4.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: February 23, 2021
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
  • Patent number: 10918971
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: February 16, 2021
    Assignee: Cytiva BioProcess R&D AB
    Inventor: Sophia Hober
  • Patent number: 10889644
    Abstract: The present invention provides for a humanized anti-BAG3 antibody or a fragment thereof, pharmaceutical compositions comprising said antibody and its use as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic, cardiovascular and/or degenerative nature.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: BIOUNIVERSA S.R.L.
    Inventors: Maria Caterina Turco, Alessandra Rosati, Vincenzo De Laurenzi, Gianluca Sala
  • Patent number: 10875911
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gavin Thurston, Christopher Daly
  • Patent number: 10865253
    Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 15, 2020
    Assignee: GENMAB A/S
    Inventors: Aran F. Labrijn, Joyce I. Meesters, Janine Schuurman, Paul Parren, Anthony Armstrong, Matthew Bunce, Mark Chiu, Thomas Nesspor, Adam Zwolak
  • Patent number: 10842881
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 24, 2020
    Assignee: Rinat Neuroscience Corp.
    Inventors: Santiago Esteban Farias, Meritxell Galindo Casas, Pavel Strop
  • Patent number: 10808026
    Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 20, 2020
    Assignee: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • Patent number: 10745470
    Abstract: The present invention relates to improved antibodies specific for Tenascin-C (TnC), in particular domain specific anti-TnC antibodies with improved cross-species reactivity. In addition, the invention relates to polynuleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies and methods of using them in the treatment of disease.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Patent number: 10738133
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10738078
    Abstract: In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, comprising: a) subjecting the mixture to a first chromatography step; b) recovering the protein of interest in an elution solution; c) adding caprylic acid to the elution solution to form a contaminant precipitate; d) removing the contaminant precipitate from the elution solution; and e) subjecting the post-precipitated elution solution to a second chromatography column, thereby purifying the protein of interest.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 11, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ji Zheng, Jue Wang
  • Patent number: 10732182
    Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein, or a caspase and an inhibitor of caspase-IAP heterodimer protein in the cell. The methods provide a predictive tool to identify patients likely to respond to drugs that perturb heterodimer binding and induce apoptosis in a cancer cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 4, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventor: Michael H. Cardone
  • Patent number: 10722569
    Abstract: Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 28, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Paula I. Watnick
  • Patent number: 10676528
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 9, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Haiying Qin, Terry J. Fry
  • Patent number: 10670604
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 2, 2020
    Assignee: AD Pharmaceutical Co., Inc.
    Inventors: Baiyong Li, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai
  • Patent number: 10668149
    Abstract: The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Parul Doshi, Henk M. Lokhorst, Tuna Mutis
  • Patent number: 10653791
    Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 19, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Mark J. Selby, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
  • Patent number: 10640574
    Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 5, 2020
    Assignee: Taurus Biosciences, LLC
    Inventors: Omar Bazirgan, Miguel De Los Rios
  • Patent number: 10618964
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Veerle Compernolle, Francis Descamps
  • Patent number: 10561653
    Abstract: The present invention relates to 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 18, 2020
    Assignees: Novartis AG, Palobiofarma, S.L.
    Inventors: Sanela Bilic, Juan Alberto Camacho Gomez, John Scott Cameron, Julio Cesar Castro-Palomino Laria, Danny Roland Howard, Jr.
  • Patent number: 10562975
    Abstract: A method of treating a T-cell mediated disease in a subject by administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to CD6 is described. Humanized antibodies useful for the method are also described.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: February 18, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE CLEVELAND CLINIC FOUNDATION
    Inventors: Feng Lin, David A. Fox
  • Patent number: 10556954
    Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: February 11, 2020
    Assignee: NANOMAB TECHNOLOGY LIMITED
    Inventors: Hong Hoi Ting, Chung Lim Wong
  • Patent number: 10555713
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 11, 2020
    Assignee: FIBROGEN, INC
    Inventors: Seth Porter, John L. Stauffer
  • Patent number: 10550189
    Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
  • Patent number: 10544221
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • Patent number: 10538549
    Abstract: NNA-derived specific adducts represent an integrated biomarker of exposure to thirdhand smoke (THS) as NNA is unique to THS. The NNA-dG covalent binding adduct could serve as such a biomarker, and play a role in identifying individuals exposed to THS, thus providing critical information for early detection and prevention.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Bo Hang, Ahmed Chenna
  • Patent number: 10533057
    Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: January 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Stéphane LeClair, Jan Endell, Stefan Härtle
  • Patent number: 10533052
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
  • Patent number: 10519236
    Abstract: Disclosed herein are antibodies specific to a delta1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 31, 2019
    Assignee: New York University
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko
  • Patent number: 10517936
    Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 31, 2019
    Assignee: OBI Pharma., Inc.
    Inventors: Wei Han Lee, Nan-Hsuan Wang, Chung Hao Chang, Yih-Huang Hsieh, Cheng Der Tony Yu, Cheng-Chi Wang, Yu-Hsin Lin, Yu-Chen Lin, I-Ju Chen
  • Patent number: 10508149
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 17, 2019
    Assignee: AnaptysBio, Inc.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Patent number: 10501744
    Abstract: The invention provides a fusion protein comprising an antigen binding domain linked to a bacteriophage decoration (Dec) protein along with a polynucleotide comprising the nucleic acid sequence of the fusion protein and a vector comprising the polynucleotide. Additionally, the invention provides a composition comprising the fusion protein and a virus-like particle (VLP), and a method of treating a disease in a mammal comprising administering a therapeutically effective amount of the composition to the mammal. The invention also provides a method of vaccinating against a disease comprising administering a composition comprising the fusion protein and a VLP encapsulating a protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: December 10, 2019
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Trevor Douglas, Benjamin Harold Schwarz, Ranjit Koliyatt, Masaki Uchida, John Alexander Avera
  • Patent number: 10494444
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 3, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 10493149
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Patent number: 10456420
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 29, 2019
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Patent number: 10429390
    Abstract: The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 1, 2019
    Assignee: Biocare Medical, LLC
    Inventor: David Tacha
  • Patent number: 10407506
    Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: September 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Yue Liu
  • Patent number: 10407500
    Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 10, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Didrerot—Paris 7
    Inventors: Anne Joutel, Søren Christensen, Thorleif Jan Pedersen
  • Patent number: 10391170
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Patent number: 10370440
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 6, 2019
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 10370408
    Abstract: The present disclosure provides compositions and methods for purifying a protein such as DNase using a chromatographic process. The methods include a single chromatographic step and the use of high concentration salt buffers.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 6, 2019
    Assignee: JHL Biotech, Inc.
    Inventors: Gregory Scott Blank, Jiun-Liang Lin